Osteosarcoma: A comprehensive review of model systems and experimental therapies
Main Article Content
Abstract
Osteosarcoma (OSA) is a highly malignant bone tumor for which more than 50% of patients have or will develop metastatic disease, resulting in an abysmal 5-year survival rate of <29%. Despite the advances in science and medicine, the etiology of OSA remains unclear. Similarly, the standard of care (surgery and chemotherapy) has changed little in the past 5 decades. This stagnation in treatment options is in part due to inadequate preclinical models for OSA; many of these models are oversimplified and do not account for the complexities of patient disease. Further, current treatments are harsh and invasive (e.g. high dose chemotherapy and potential limb removal) leading to a reduction in a patient’s quality of life (e.g. hearing loss, infertility, neuropathy), highlighting a need for developing more effective treatment strategies. Many experimental therapies have been tested in the preclinical and preclinical setting, with varying degrees of success. In this review, we will focus on pediatric and adolescent OSA, highlighting current animal models and experimental therapies.
Article Details
How to Cite
ROBBINS, Gabrielle M. et al.
Osteosarcoma: A comprehensive review of model systems and experimental therapies.
Medical Research Archives, [S.l.], v. 12, n. 11, nov. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6000>. Date accessed: 12 dec. 2024.
doi: https://doi.org/10.18103/mra.v12i11.6000.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. The lectures of Boyer upon diseases of the bones - Digital Collections - National Library of Medicine. https://collections.nlm.nih.gov/catalog/nlm:nlmuid-2544005R-bk.
2. Manchanda, A. S., Narang, R. S. & Mahajan, S. Osteosarcoma: A case report and evaluation. J. Oral Maxillofac. Pathol. 25, 374–375 (2021).
3. Abarrategi, A. et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016, 3631764 (2016).
4. Ottaviani, G. & Jaffe, N. The etiology of osteosarcoma. Cancer Treat. Res. 152, 15–32 (2009).
5. Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531–1543 (2009).
6. Ottaviani, G. & Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 152, 3–13 (2009).
7. Biermann, J. S. et al. Bone cancer. J. Natl. Compr. Canc. Netw. 11, 688–723 (2013).
8. Lindsey, B. A., Markel, J. E. & Kleinerman, E. S. Osteosarcoma Overview. Rheumatol Ther 4, 25–43 (2017).
9. Xu, Q., Gao, T., Zhang, B., Zeng, J. & Dai, M. Primary osteosarcoma in elderly patients: A report of three cases. Oncol. Lett. 18, 990–996 (2019).
10. Beird, H. C. et al. Osteosarcoma. Nat Rev Dis Primers 8, 77 (2022).
11. Wadhwa, N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian J. Orthop. 48, 247–254 (2014).
12. Bentzen, S. M. et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer 62, 194–202 (1988).
13. Misaghi, A., Goldin, A., Awad, M. & Kulidjian, A. A. Osteosarcoma: a comprehensive review. SICOT J 4, 12 (2018).
14. Tiwari, A. Current concepts in surgical treatment of osteosarcoma. J Clin Orthop Trauma 3, 4–9 (2012).
15. Smeland, S. et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur. J. Cancer 39, 488–494 (2003).
16. Petrilli, A. S. et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68, 733–737 (1991).
17. Jeffree, G. M., Price, C. H. & Sissons, H. A. The metastatic patterns of osteosarcoma. Br. J. Cancer 32, 87–107 (1975).
18. Serpico, R. et al. Metastasis of osteosarcoma to the abdomen: A report of two cases and a review of the literature. Case Rep. Oncol. 14, 647–658 (2021).
19. Sheng, G., Gao, Y., Yang, Y. & Wu, H. Osteosarcoma and metastasis. Front. Oncol. 11, 780264 (2021).
20. Mohseny, A. B. et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. 91, 1195–1205 (2011).
21. Kapałczyńska, M. et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch. Med. Sci. 14, 910–919 (2018).
22. Ye, L., Swingen, C. & Zhang, J. Induced pluripotent stem cells and their potential for basic and clinical sciences. Curr. Cardiol. Rev. 9, 63–72 (2013).
23. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
24. Pang, L. K., Pena, M., Zhao, R. & Lee, D.-F. Modeling of osteosarcoma with induced pluripotent stem cells. Stem Cell Res. 49, 102006 (2020).
25. Lee, D.-F. et al. Modeling familial cancer with induced pluripotent stem cells. Cell 161, 240–254 (2015).
26. Zhou, R. et al. Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells. J. Vis. Exp. (2018) doi:10.3791/57664.
27. Tu, J. et al. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proc. Natl. Acad. Sci. U. S. A. 119, e2117857119 (2022).
28. Jewell, B. E. et al. Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome. PLoS Genet. 17, e1009971 (2021).
29. Becklin, K. L. et al. Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. CRISPR J 5, 517–535 (2022).
30. Baxter, M. et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J. Hepatol. 62, 581–589 (2015).
31. Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S. & Searson, P. C. In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Front Bioeng Biotechnol 4, 12 (2016).
32. Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4, 309–324 (2009).
33. LaBarbera, D. V., Reid, B. G. & Yoo, B. H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin. Drug Discov. 7, 819–830 (2012).
34. Arai, K., Sakamoto, R., Kubota, D. & Kondo, T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics 13, 2351–2360 (2013).
35. Gebhard, C., Gabriel, C. & Walter, I. Morphological and Immunohistochemical Characterization of Canine Osteosarcoma Spheroid Cell Cultures. Anat. Histol. Embryol. 45, 219–230 (2016).
36. Kundu, B. et al. Mechanical Property of Hydrogels and the Presence of Adipose Stem Cells in Tumor Stroma Affect Spheroid Formation in the 3D Osteosarcoma Model. ACS Appl. Mater. Interfaces 11, 14548–14559 (2019).
37. Gebhard, C. et al. Comparative proteome analysis of monolayer and spheroid culture of canine osteosarcoma cells. J. Proteomics 177, 124–136 (2018).
38. Freeman, F. E., Burdis, R., Mahon, O. R., Kelly, D. J. & Artzi, N. A Spheroid Model of Early and Late-Stage Osteosarcoma Mimicking the Divergent Relationship between Tumor Elimination and Bone Regeneration. Adv. Healthc. Mater. 11, e2101296 (2022).
39. Rimann, M. et al. An in vitro osteosarcoma 3D microtissue model for drug development. J. Biotechnol. 189, 129–135 (2014).
40. Fischetti, T., Di Pompo, G., Baldini, N., Avnet, S. & Graziani, G. 3D Printing and Bioprinting to Model Bone Cancer: The Role of Materials and Nanoscale Cues in Directing Cell Behavior. Cancers 13, (2021).
41. Safhi, A. Y. Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives. Pharmaceuticals 15, (2022).
42. Contessi Negrini, N. et al. An Osteosarcoma Model by 3D Printed Polyurethane Scaffold and In Vitro Generated Bone Extracellular Matrix. Cancers 14, (2022).
43. Delgrosso, E. et al. 3D bioprinted osteosarcoma model for experimental boron neutron capture therapy (BNCT) applications: Preliminary assessment. J. Biomed. Mater. Res. B Appl. Biomater. 111, 1571–1580 (2023).
44. Ma, Y. et al. The Dual Effect of 3D-Printed Biological Scaffolds Composed of Diverse Biomaterials in the Treatment of Bone Tumors. Int. J. Nanomedicine 18, 293–305 (2023).
45. Kersten, K., de Visser, K. E., van Miltenburg, M. H. & Jonkers, J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 9, 137–153 (2017).
46. Poste, G. & Fidler, I. J. The pathogenesis of cancer metastasis. Nature 283, 139–146 (1980).
47. Asai, T. et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int. J. Cancer 76, 418–422 (1998).
48. Khanna, C. et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 18, 261–271 (2000).
49. Luu, H. H. et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis 22, 319–329 (2005).
50. McAllister, R. M. et al. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27, 397–402 (1971).
51. Manara, M. C. et al. Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone 26, 215–220 (2000).
52. Du, L., Fan, Q., Tu, B., Yan, W. & Tang, T. Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2. Int. J. Clin. Exp. Pathol. 7, 2871–2882 (2014).
53. Billiau, A. et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob. Agents Chemother. 12, 11–15 (1977).
54. Wulf-Goldenberg, A., Hoffmann, J., Becker, M., Brzezicha, B. & Walther, W. Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis. Methods Mol. Biol. 2294, 43–58 (2021).
55. Szewczyk, M., Lechowski, R. & Zabielska, K. What do we know about canine osteosarcoma treatment? Review. Vet. Res. Commun. 39, 61–67 (2015).
56. Simpson, S. et al. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet. Scand. 59, 71 (2017).
57. Bulaklak, K. & Gersbach, C. A. The once and future gene therapy. Nat. Commun. 11, 5820 (2020).
58. Broadhead, M. L., Clark, J. C. M., Choong, P. F. M. & Dass, C. R. Making gene therapy for osteosarcoma a reality. Expert Rev. Anticancer Ther. 10, 477–480 (2010).
59. Aubrey, B. J., Strasser, A. & Kelly, G. L. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb. Perspect. Med. 6, (2016).
60. Mirabello, L. et al. Germline TP53 variants and susceptibility to osteosarcoma. J. Natl. Cancer Inst. 107, (2015).
61. Phelan, A., Elliott, G. & O’Hare, P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16, 440–443 (1998).
62. Densmore, C. L. et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8, 619–627 (2001).
63. Ganjavi, H. et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 13, 415–419 (2006).
64. Tsuchiya, H., Mori, Y., Ueda, Y., Okada, G. & Tomita, K. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res. 20, 235–242 (2000).
65. Song, S. U. & Boyce, F. M. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp. Mol. Med. 33, 46–53 (2001).
66. Ye, S. et al. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. Cancer Chemother. Pharmacol. 77, 349–356 (2016).
67. Ballatori, S. E. & Hinds, P. W. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal Transduct. Target. Ther. 1, 16001 (2016).
68. Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29, 946–960 (2022).
69. Lee, E. Y. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288–294 (1992).
70. Zhang, W., Moore, L. & Ji, P. Mouse models for cancer research. Chin. J. Cancer 30, 149–152 (2011).
71. Williams, B. O. et al. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet. 7, 480–484 (1994).
72. Feugeas, O. et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J. Clin. Oncol. 14, 467–472 (1996).
73. Ren, W. & Gu, G. Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis. Eur. J. Cancer Care 26, (2017).
74. Xu, H. J. et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 56, 2245–2249 (1996).
75. Craig, C. et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 16, 265–272 (1998).
76. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3, 4–10 (2005).
77. Mei, J. et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp. Oncol. 30, 29–34 (2008).
78. Peng, N. et al. Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway. Am. J. Transl. Res. 8, 1005–1015 (2016).
79. Liu, T.-C. et al. APE1 distinguishes DNA substrates in exonucleolytic cleavage by induced space-filling. Nat. Commun. 12, 601 (2021).
80. Wang, D., Luo, M. & Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 3, 679–686 (2004).
81. Dai, N. et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma 60, 384–394 (2013).
82. Liang, W., Li, C., Li, M., Wang, D. & Zhong, Z. MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression. Onco. Targets. Ther. 12, 7203–7214 (2019).
83. Wang, D., Zhong, Z.-Y., Li, M.-X., Xiang, D.-B. & Li, Z.-P. Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci. 98, 1993–2001 (2007).
84. Behjati, S. et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat. Commun. 8, 15936 (2017).
85. Farzaei, M. H., Bahramsoltani, R., Rahimi, R., Abbasabadi, F. & Abdollahi, M. A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders. Curr. Top. Med. Chem. 16, 1924–1942 (2016).
86. Papachristou, D. J., Batistatou, A., Sykiotis, G. P., Varakis, I. & Papavassiliou, A. G. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 32, 364–371 (2003).
87. Dass, C. R., Khachigian, L. M. & Choong, P. F. M. c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol. Cancer Res. 6, 1289–1292 (2008).
88. Dass, C. R., Khachigian, L. M. & Choong, P. F. M. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol. Cancer Ther. 7, 1909–1912 (2008).
89. Tang, Q. et al. miR-223/Hsp70/JNK/JUN/m iR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin. Biochem. Biophys. Res. Commun. 497, 827–834 (2018).
90. Ren, L. & Khanna, C. Role of ezrin in osteosarcoma metastasis. Adv. Exp. Med. Biol. 804, 181–201 (2014).
91. Ren, L. et al. Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma. Cancer Res. 72, 1001–1012 (2012).
92. Khanna, C. et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10, 182–186 (2004).
93. Lo Vasco, V. R., Leopizzi, M., Puggioni, C. & Della Rocca, C. Ezrin silencing remodulates the expression of Phosphoinositide-specific Phospholipase C enzymes in human osteosarcoma cell lines. J. Cell Commun. Signal. 8, 219–229 (2014).
94. Wu, M.-S. et al. CDC20 and its downstream genes: potential prognosis factors of osteosarcoma. Int. J. Clin. Oncol. 24, 1479–1489 (2019).
95. Wang, H., Liu, Z., Wu, P., Wang, H. & Ren, W. NUSAP1 Accelerates Osteosarcoma Cell Proliferation and Cell Cycle Progression via Upregulating CDC20 and Cyclin A2. Onco. Targets. Ther. 14, 3443–3454 (2021).
96. Liu Y., Ding J.-Y., Shen W.-L., Zhao X. & Fan S.-W. [Knockdown of cyclin A2 expression by small interfering RNA in MG-63 cells]. Zhonghua Zhong Liu Za Zhi 29, 670–675 (2007).
97. Shekhar, R. et al. The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression. J. Biol. Chem. 294, 4381–4400 (2019).
98. Mahmood, N., Mihalcioiu, C. & Rabbani, S. A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front. Oncol. 8, 24 (2018).
99. Haeckel, C. et al. Protease expression in dedifferentiated parosteal osteosarcoma. Arch. Pathol. Lab. Med. 123, 213–221 (1999).
100. Matsuyama, A., Wood, G. A., Speare, R., Schott, C. R. & Mutsaers, A. J. Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma. PLoS One 17, e0273811 (2022).
101. Dass, C. R. et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin. Exp. Metastasis 22, 643–652 (2005).
102. Borgatti, A. et al. Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. Mol. Cancer Ther. 16, 956–965 (2017).
103. de Bock, C. E. et al. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J. 272, 3572–3582 (2005).
104. Endo-Munoz, L. et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PLoS One 10, e0133592 (2015).
105. Jia, S.-F. et al. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 9, 260–266 (2002).
106. Worth, L. L., Jia, S. F., Zhou, Z., Chen, L. & Kleinerman, E. S. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res. 6, 3713–3718 (2000).
107. Tsuji, H. et al. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther. 9, 747–755 (2002).
108. Charissoux, J. L., Grossin, L., Leboutet, M. J. & Rigaud, M. Treatment of experimental osteosarcoma tumors in rat by herpes simplex thymidine kinase gene transfer and ganciclovir. Anticancer Res. 19, 77–80 (1999).
109. Ramnaraine, M. et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res. 63, 6847–6854 (2003).
110. Ternovoi, V. V., Curiel, D. T., Smith, B. F. & Siegal, G. P. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab. Invest. 86, 748–766 (2006).
111. Li, H. et al. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. Oncogene 40, 2785–2802 (2021).
112. Martínez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669–680 (2021).
113. Berger, M. F. & Mardis, E. R. The emerging clinical relevance of genomics in cancer medicine. Nat. Rev. Clin. Oncol. 15, 353–365 (2018).
114. Li, Q. & Kang, C. Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery. Int. J. Mol. Sci. 21, (2020).
115. Liu, G.-H., Chen, T., Zhang, X., Ma, X.-L. & Shi, H.-S. Small molecule inhibitors targeting the cancers. MedComm (2020) 3, e181 (2022).
116. Cohen, P., Cross, D. & Jänne, P. A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551–569 (2021).
117. Steeghs, N., Nortier, J. W. R. & Gelderblom, H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14, 942–953 (2007).
118. Li, S. Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. Front. Oncol. 11, 664853 (2021).
119. Wang, G. et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int. J. Cancer 145, 979–993 (2019).
120. Wang, G. et al. Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo. Front. Pharmacol. 12, 798837 (2021).
121. Long, Z.-Y. et al. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review. Ann. Palliat. Med. 10, 7073–7082 (2021).
122. Tian, S. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102, 1374–1380 (2011).
123. Aoyama, T. & Yoshikawa, T. Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. Nat. Rev. Clin. Oncol. 13, 268–270 (2016).
124. Liu, K. et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 8, e3015 (2017).
125. Xie, L. et al. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist 24, e542–e550 (2019).
126. Geller, J. I. et al. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124, 4548–4555 (2018).
127. Keating, G. M. Axitinib: a review in advanced renal cell carcinoma. Drugs 75, 1903–1913 (2015).
128. Choueiri, T. K. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr. Opin. Investig. Drugs 9, 658–671 (2008).
129. Ranieri, G. et al. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. Int. J. Mol. Sci. 18, (2017).
130. Fioramonti, M. et al. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Sci. Rep. 8, 4177 (2018).
131. Wang, J.-H., Zeng, Z., Sun, J., Chen, Y. & Gao, X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol. Res. 173, 105869 (2021).
132. Italiano, A. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446–455 (2020).
133. Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
134. Morton, C. L. et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 566–571 (2012).
135. Fox, E. et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 28, 5174–5181 (2010).
136. van Cruijsen, H. et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur. J. Cancer 46, 901–911 (2010).
137. Choi, K.-M. et al. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer. Int. J. Mol. Sci. 21, (2020).
138. Marley, K., Gullaba, J., Seguin, B., Gelberg, H. B. & Helfand, S. C. Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs. Transl. Oncol. 8, 231–238 (2015).
139. Ding, X. et al. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study. Anticancer Drugs 34, 877–882 (2023).
140. Zhao, Y. & Adjei, A. A. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 20, 660–673 (2015).
141. Iqbal, N. & Iqbal, N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 357027 (2014).
142. Gai, Q.-J. et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther 7, 33 (2022).
143. Benini, S. et al. Redundancy of autocrine loops in human osteosarcoma cells. Int. J. Cancer 80, 581–588 (1999).
144. Bond, M. et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr. Blood Cancer 50, 254–258 (2008).
145. Gobin, B. et al. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PLoS One 9, e90795 (2014).
146. Suyama, K. & Iwase, H. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control 25, 1073274818789361 (2018).
147. Gaspar, N. et al. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆. ESMO Open 6, 100250 (2021).
148. Gaspar, N. et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 22, 1312–1321 (2021).
149. Yoon, H.-Y., Park, S., Kim, D. S. & Song, J. W. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir. Res. 19, 203 (2018).
150. Zhang, W. et al. Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth. Cell Rep. 24, 1266–1277.e5 (2018).
151. Kallus, S. et al. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine 14, 2632–2643 (2018).
152. Sloan, B. & Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9, 1324–1335 (2008).
153. Kumar, S. et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17, 5656–5667 (2011).
154. Longhi, A. et al. Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncol. 58, 124–128 (2019).
155. Wilhelm, S. M. et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245–255 (2011).
156. Pan, P.-J., Liu, Y.-C. & Hsu, F.-T. Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. J. Clin. Med. Res. 8, (2019).
157. Duffaud, F. et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 20, 120–133 (2019).
158. Davis, L. E. et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J. Clin. Oncol. 37, 1424–1431 (2019).
159. Coventon, J. A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. J Bone Oncol 8, 4–7 (2017).
160. Grignani, G. et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 16, 98–107 (2015).
161. Papaetis, G. S. & Syrigos, K. N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23, 377–389 (2009).
162. Motzer, R. J., Escudier, B., Gannon, A. & Figlin, R. A. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist 22, 41–52 (2017).
163. Kumar, R. M. R., Arlt, M. J., Kuzmanov, A., Born, W. & Fuchs, B. Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model. Am. J. Cancer Res. 5, 2156–2168 (2015).
164. Duan, X. L., Guo, J. P., Li, F., Xiu, C. & Wang, H. Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice. Future Oncol. 16, 1815–1824 (2020).
165. Penel-Page, M. et al. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer 15, 854 (2015).
166. McCarthy, E. F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 26, 154–158 (2006).
167. Esfahani, K. et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 27, S87–S97 (2020).
168. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327 (2010).
169. Nelson, P. N. et al. Monoclonal antibodies. Mol. Pathol. 53, 111–117 (2000).
170. Zahavi, D. & Weiner, L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel) 9, (2020).
171. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987–989 (2001).
172. Raouf, S., Bertelli, G., Ograbek, A., Field, P. & Tran, I. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncol. 15, 543–561 (2019).
173. Navid, F. et al. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int. J. Cancer 141, 1469–1477 (2017).
174. Pfister, N. T. et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 29, 1298–1315 (2015).
175. Lowery, C. D. et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget 10, 5523–5533 (2019).
176. Hashimoto, K., Nishimura, S. & Akagi, M. Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma. Diagnostics (Basel) 10, (2020).
177. Wen, Y. et al. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. Cancer Lett. 547, 215887 (2022).
178. Shimizu, T. et al. The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma. J. Pediatr. Surg. 52, 2047–2050 (2017).
179. Dhupkar, P., Gordon, N., Stewart, J. & Kleinerman, E. S. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 7, 2654–2664 (2018).
180. Zhang, M.-L., Chen, L., Li, Y.-J. & Kong, D.-L. PD L1/PD 1 axis serves an important role in natural killer cell induced cytotoxicity in osteosarcoma. Oncol. Rep. 42, 2049–2056 (2019).
181. Lussier, D. M. et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J. Immunother. 38, 96–106 (2015).
182. Liu, X. et al. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ. Health Prev. Med. 24, 79 (2019).
183. Yoshida, K. et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer 20, 25 (2020).
184. Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–1501 (2017).
185. Le Cesne, A. et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur. J. Cancer 119, 151–157 (2019).
186. Geoerger, B. et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol. 21, 134–144 (2020).
187. Davis, K. L. et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 541–550 (2020).
188. Boye, K. et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol. Immunother. 70, 2617–2624 (2021).
189. Contardi, E. et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer 117, 538–550 (2005).
190. Kawano, M., Itonaga, I., Iwasaki, T. & Tsumura, H. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol. Rep. 29, 1001–1006 (2013).
191. Eroglu, Z. et al. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur. J. Cancer 51, 2689–2697 (2015).
192. Merchant, M. S. et al. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin. Cancer Res. 22, 1364–1370 (2016).
193. Cui, J. et al. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. J. Orthop. Res. 38, 2362–2372 (2020).
194. Slemmons, K. K., Mukherjee, S., Meltzer, P., Purcell, J. W. & Helman, L. J. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr. Blood Cancer 68, e28771 (2021).
195. Hingorani, P. et al. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol. Cancer Ther. 20, 535–540 (2021).
196. Demetri, G. D. et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin. Cancer Res. 27, 3556–3566 (2021).
197. Tabak, S. A., Khalifa, S. E. & Fathy, Y. HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients. Open Access Maced J Med Sci 6, 1555–1560 (2018).
198. Park, J. A. & Cheung, N.-K. V. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J. Hematol. Oncol. 13, 172 (2020).
199. Ebb, D. et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J. Clin. Oncol. 30, 2545–2551 (2012).
200. Wen, Y. H. et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum. Pathol. 38, 1184–1191 (2007).
201. Sevelda, F. et al. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J. Exp. Clin. Cancer Res. 34, 134 (2015).
202. Wang, S. et al. Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. Acta Biochim. Biophys. Sin. 53, 317–324 (2021).
203. Pahl, J. H. W. et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin. Cancer Res. 18, 432–441 (2012).
204. Li, Y.-S., Liu, Q., He, H.-B. & Luo, W. The possible role of insulin-like growth factor-1 in osteosarcoma. Curr. Probl. Cancer 43, 228–235 (2019).
205. Houghton, P. J. et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 921–926 (2010).
206. Kolb, E. A. et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr. Blood Cancer 55, 67–75 (2010).
207. Malempati, S. et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 30, 256–262 (2012).
208. Kolb, E. A. et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr. Blood Cancer 61, 1816–1821 (2014).
209. Kopp, L. M. et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children’s Oncology Group. Eur. J. Cancer 121, 177–183 (2019).
210. Smeester, B. A. et al. SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. Oncogene 39, 1049–1062 (2020).
211. Lussier, D. M., Johnson, J. L., Hingorani, P. & Blattman, J. N. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3, 21 (2015).
212. Xie, M. et al. Identification of genes contributing to cisplatin resistance in osteosarcoma cells. FEBS Open Bio 13, 164–173 (2023).
213. Clavijo, P. E. et al. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. Cancer Immunol Res 7, 282–291 (2019).
214. Liu, J. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022).
215. Thamm, D. H. et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin. Cancer Res. 11, 4827–4834 (2005).
216. Hashii, Y. et al. WT1 peptide immunotherapy for cancer in children and young adults. Pediatr. Blood Cancer 55, 352–355 (2010).
217. Himoudi, N. et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin. Transl. Oncol. 14, 271–279 (2012).
218. Finocchiaro, L. M. E., Villaverde, M. S., Gil-Cardeza, M. L., Riveros, M. D. & Glikin, G. C. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas. Res. Vet. Sci. 91, 230–234 (2011).
219. Gentschev, I. et al. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 4, 84–89 (2013).
220. Cascini, C. et al. Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma. J. Exp. Clin. Cancer Res. 42, 154 (2023).
221. Mason, N. J. et al. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clin. Cancer Res. 22, 4380–4390 (2016).
222. Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).
223. Heymann, M.-F., Lézot, F. & Heymann, D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell. Immunol. 343, 103711 (2019).
224. Lu, Y. et al. Novel Immunotherapies for Osteosarcoma. Front. Oncol. 12, 830546 (2022).
225. Fritzsching, B. et al. CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology 4, e990800 (2015).
226. Sarnaik, A. A., Hwu, P., Mulé, J. J. & Pilon-Thomas, S. Tumor-infiltrating lymphocytes: A new hope. Cancer Cell 42, 1315–1318 (2024).
227. Park, J. A. & Cheung, N.-K. V. Promise and challenges of T cell immunotherapy for osteosarcoma. Int. J. Mol. Sci. 24, (2023).
228. Casanova, J. M. et al. Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival. Cancers 13, (2021).
229. Zhou, X., Wu, J., Duan, C. & Liu, Y. Retrospective analysis of adoptive TIL therapy plus anti-PD1 therapy in patients with chemotherapy-resistant metastatic osteosarcoma. J. Immunol. Res. 2020, 7890985 (2020).
230. Wang, C., Li, M., Wei, R. & Wu, J. Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. J Bone Oncol 25, 100332 (2020).
231. Yu, S. & Yao, X. Advances on immunotherapy for osteosarcoma. Mol. Cancer 23, 192 (2024).
232. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
233. Rohaan, M. W., Wilgenhof, S. & Haanen, J. B. A. G. Adoptive cellular therapies: the current landscape. Virchows Arch. 474, 449–461 (2019).
234. Watanabe, K. et al. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells. Cancer Sci. 110, 40–51 (2019).
235. Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer 9, (2021).
236. Rafei, H., Daher, M. & Rezvani, K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br. J. Haematol. 193, 216–230 (2021).
237. Terlikowska, K. M., Dobrzycka, B. & Terlikowski, S. J. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. Int. J. Mol. Sci. 22, (2021).
238. Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689–702 (2009).
239. Ahmed, N. et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779–1787 (2009).
240. Rainusso, N. et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19, 212–217 (2012).
241. Talbot, L. J. et al. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells. Front. Immunol. 12, 691741 (2021).
242. Zhang, Q. et al. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer 22, 1124 (2022).
243. Hidalgo, L. et al. Switchable CAR T cell strategy against osteosarcoma. Cancer Immunol. Immunother. 72, 2623–2633 (2023).
244. Chulanetra, M. et al. GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. Am. J. Cancer Res. 10, 674–687 (2020).
245. Fernández, L. et al. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. Clin. Cancer Res. 23, 5824–5835 (2017).
246. Huang, G. et al. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72, 271–281 (2012).
247. Wang, Y. et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J. Exp. Clin. Cancer Res. 38, 168 (2019).
248. Mensali, N. et al. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nat. Commun. 14, 3375 (2023).
249. Zhang, X., Zhang, H., Lan, H., Wu, J. & Xiao, Y. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front. Immunol. 14, 1101495 (2023).
S
250. Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).
251. Wang, L., Li, W. & Pan, Y. The Eph/Ephrin system in primary bone tumor and bone cancer pain. Aging 15, 7324–7332 (2023).
2. Manchanda, A. S., Narang, R. S. & Mahajan, S. Osteosarcoma: A case report and evaluation. J. Oral Maxillofac. Pathol. 25, 374–375 (2021).
3. Abarrategi, A. et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016, 3631764 (2016).
4. Ottaviani, G. & Jaffe, N. The etiology of osteosarcoma. Cancer Treat. Res. 152, 15–32 (2009).
5. Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531–1543 (2009).
6. Ottaviani, G. & Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 152, 3–13 (2009).
7. Biermann, J. S. et al. Bone cancer. J. Natl. Compr. Canc. Netw. 11, 688–723 (2013).
8. Lindsey, B. A., Markel, J. E. & Kleinerman, E. S. Osteosarcoma Overview. Rheumatol Ther 4, 25–43 (2017).
9. Xu, Q., Gao, T., Zhang, B., Zeng, J. & Dai, M. Primary osteosarcoma in elderly patients: A report of three cases. Oncol. Lett. 18, 990–996 (2019).
10. Beird, H. C. et al. Osteosarcoma. Nat Rev Dis Primers 8, 77 (2022).
11. Wadhwa, N. Osteosarcoma: Diagnostic dilemmas in histopathology and prognostic factors. Indian J. Orthop. 48, 247–254 (2014).
12. Bentzen, S. M. et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer 62, 194–202 (1988).
13. Misaghi, A., Goldin, A., Awad, M. & Kulidjian, A. A. Osteosarcoma: a comprehensive review. SICOT J 4, 12 (2018).
14. Tiwari, A. Current concepts in surgical treatment of osteosarcoma. J Clin Orthop Trauma 3, 4–9 (2012).
15. Smeland, S. et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur. J. Cancer 39, 488–494 (2003).
16. Petrilli, A. S. et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer 68, 733–737 (1991).
17. Jeffree, G. M., Price, C. H. & Sissons, H. A. The metastatic patterns of osteosarcoma. Br. J. Cancer 32, 87–107 (1975).
18. Serpico, R. et al. Metastasis of osteosarcoma to the abdomen: A report of two cases and a review of the literature. Case Rep. Oncol. 14, 647–658 (2021).
19. Sheng, G., Gao, Y., Yang, Y. & Wu, H. Osteosarcoma and metastasis. Front. Oncol. 11, 780264 (2021).
20. Mohseny, A. B. et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. 91, 1195–1205 (2011).
21. Kapałczyńska, M. et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch. Med. Sci. 14, 910–919 (2018).
22. Ye, L., Swingen, C. & Zhang, J. Induced pluripotent stem cells and their potential for basic and clinical sciences. Curr. Cardiol. Rev. 9, 63–72 (2013).
23. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676 (2006).
24. Pang, L. K., Pena, M., Zhao, R. & Lee, D.-F. Modeling of osteosarcoma with induced pluripotent stem cells. Stem Cell Res. 49, 102006 (2020).
25. Lee, D.-F. et al. Modeling familial cancer with induced pluripotent stem cells. Cell 161, 240–254 (2015).
26. Zhou, R. et al. Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells. J. Vis. Exp. (2018) doi:10.3791/57664.
27. Tu, J. et al. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proc. Natl. Acad. Sci. U. S. A. 119, e2117857119 (2022).
28. Jewell, B. E. et al. Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome. PLoS Genet. 17, e1009971 (2021).
29. Becklin, K. L. et al. Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. CRISPR J 5, 517–535 (2022).
30. Baxter, M. et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J. Hepatol. 62, 581–589 (2015).
31. Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S. & Searson, P. C. In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. Front Bioeng Biotechnol 4, 12 (2016).
32. Friedrich, J., Seidel, C., Ebner, R. & Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4, 309–324 (2009).
33. LaBarbera, D. V., Reid, B. G. & Yoo, B. H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin. Drug Discov. 7, 819–830 (2012).
34. Arai, K., Sakamoto, R., Kubota, D. & Kondo, T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics 13, 2351–2360 (2013).
35. Gebhard, C., Gabriel, C. & Walter, I. Morphological and Immunohistochemical Characterization of Canine Osteosarcoma Spheroid Cell Cultures. Anat. Histol. Embryol. 45, 219–230 (2016).
36. Kundu, B. et al. Mechanical Property of Hydrogels and the Presence of Adipose Stem Cells in Tumor Stroma Affect Spheroid Formation in the 3D Osteosarcoma Model. ACS Appl. Mater. Interfaces 11, 14548–14559 (2019).
37. Gebhard, C. et al. Comparative proteome analysis of monolayer and spheroid culture of canine osteosarcoma cells. J. Proteomics 177, 124–136 (2018).
38. Freeman, F. E., Burdis, R., Mahon, O. R., Kelly, D. J. & Artzi, N. A Spheroid Model of Early and Late-Stage Osteosarcoma Mimicking the Divergent Relationship between Tumor Elimination and Bone Regeneration. Adv. Healthc. Mater. 11, e2101296 (2022).
39. Rimann, M. et al. An in vitro osteosarcoma 3D microtissue model for drug development. J. Biotechnol. 189, 129–135 (2014).
40. Fischetti, T., Di Pompo, G., Baldini, N., Avnet, S. & Graziani, G. 3D Printing and Bioprinting to Model Bone Cancer: The Role of Materials and Nanoscale Cues in Directing Cell Behavior. Cancers 13, (2021).
41. Safhi, A. Y. Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives. Pharmaceuticals 15, (2022).
42. Contessi Negrini, N. et al. An Osteosarcoma Model by 3D Printed Polyurethane Scaffold and In Vitro Generated Bone Extracellular Matrix. Cancers 14, (2022).
43. Delgrosso, E. et al. 3D bioprinted osteosarcoma model for experimental boron neutron capture therapy (BNCT) applications: Preliminary assessment. J. Biomed. Mater. Res. B Appl. Biomater. 111, 1571–1580 (2023).
44. Ma, Y. et al. The Dual Effect of 3D-Printed Biological Scaffolds Composed of Diverse Biomaterials in the Treatment of Bone Tumors. Int. J. Nanomedicine 18, 293–305 (2023).
45. Kersten, K., de Visser, K. E., van Miltenburg, M. H. & Jonkers, J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 9, 137–153 (2017).
46. Poste, G. & Fidler, I. J. The pathogenesis of cancer metastasis. Nature 283, 139–146 (1980).
47. Asai, T. et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int. J. Cancer 76, 418–422 (1998).
48. Khanna, C. et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 18, 261–271 (2000).
49. Luu, H. H. et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis 22, 319–329 (2005).
50. McAllister, R. M. et al. Cultivation in vitro of cells derived from a human osteosarcoma. Cancer 27, 397–402 (1971).
51. Manara, M. C. et al. Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. Bone 26, 215–220 (2000).
52. Du, L., Fan, Q., Tu, B., Yan, W. & Tang, T. Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2. Int. J. Clin. Exp. Pathol. 7, 2871–2882 (2014).
53. Billiau, A. et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob. Agents Chemother. 12, 11–15 (1977).
54. Wulf-Goldenberg, A., Hoffmann, J., Becker, M., Brzezicha, B. & Walther, W. Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis. Methods Mol. Biol. 2294, 43–58 (2021).
55. Szewczyk, M., Lechowski, R. & Zabielska, K. What do we know about canine osteosarcoma treatment? Review. Vet. Res. Commun. 39, 61–67 (2015).
56. Simpson, S. et al. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet. Scand. 59, 71 (2017).
57. Bulaklak, K. & Gersbach, C. A. The once and future gene therapy. Nat. Commun. 11, 5820 (2020).
58. Broadhead, M. L., Clark, J. C. M., Choong, P. F. M. & Dass, C. R. Making gene therapy for osteosarcoma a reality. Expert Rev. Anticancer Ther. 10, 477–480 (2010).
59. Aubrey, B. J., Strasser, A. & Kelly, G. L. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb. Perspect. Med. 6, (2016).
60. Mirabello, L. et al. Germline TP53 variants and susceptibility to osteosarcoma. J. Natl. Cancer Inst. 107, (2015).
61. Phelan, A., Elliott, G. & O’Hare, P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16, 440–443 (1998).
62. Densmore, C. L. et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther. 8, 619–627 (2001).
63. Ganjavi, H. et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 13, 415–419 (2006).
64. Tsuchiya, H., Mori, Y., Ueda, Y., Okada, G. & Tomita, K. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res. 20, 235–242 (2000).
65. Song, S. U. & Boyce, F. M. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp. Mol. Med. 33, 46–53 (2001).
66. Ye, S. et al. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. Cancer Chemother. Pharmacol. 77, 349–356 (2016).
67. Ballatori, S. E. & Hinds, P. W. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal Transduct. Target. Ther. 1, 16001 (2016).
68. Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29, 946–960 (2022).
69. Lee, E. Y. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288–294 (1992).
70. Zhang, W., Moore, L. & Ji, P. Mouse models for cancer research. Chin. J. Cancer 30, 149–152 (2011).
71. Williams, B. O. et al. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet. 7, 480–484 (1994).
72. Feugeas, O. et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J. Clin. Oncol. 14, 467–472 (1996).
73. Ren, W. & Gu, G. Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis. Eur. J. Cancer Care 26, (2017).
74. Xu, H. J. et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 56, 2245–2249 (1996).
75. Craig, C. et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 16, 265–272 (1998).
76. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3, 4–10 (2005).
77. Mei, J. et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp. Oncol. 30, 29–34 (2008).
78. Peng, N. et al. Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway. Am. J. Transl. Res. 8, 1005–1015 (2016).
79. Liu, T.-C. et al. APE1 distinguishes DNA substrates in exonucleolytic cleavage by induced space-filling. Nat. Commun. 12, 601 (2021).
80. Wang, D., Luo, M. & Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 3, 679–686 (2004).
81. Dai, N. et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma 60, 384–394 (2013).
82. Liang, W., Li, C., Li, M., Wang, D. & Zhong, Z. MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression. Onco. Targets. Ther. 12, 7203–7214 (2019).
83. Wang, D., Zhong, Z.-Y., Li, M.-X., Xiang, D.-B. & Li, Z.-P. Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo. Cancer Sci. 98, 1993–2001 (2007).
84. Behjati, S. et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat. Commun. 8, 15936 (2017).
85. Farzaei, M. H., Bahramsoltani, R., Rahimi, R., Abbasabadi, F. & Abdollahi, M. A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders. Curr. Top. Med. Chem. 16, 1924–1942 (2016).
86. Papachristou, D. J., Batistatou, A., Sykiotis, G. P., Varakis, I. & Papavassiliou, A. G. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 32, 364–371 (2003).
87. Dass, C. R., Khachigian, L. M. & Choong, P. F. M. c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol. Cancer Res. 6, 1289–1292 (2008).
88. Dass, C. R., Khachigian, L. M. & Choong, P. F. M. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol. Cancer Ther. 7, 1909–1912 (2008).
89. Tang, Q. et al. miR-223/Hsp70/JNK/JUN/m iR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin. Biochem. Biophys. Res. Commun. 497, 827–834 (2018).
90. Ren, L. & Khanna, C. Role of ezrin in osteosarcoma metastasis. Adv. Exp. Med. Biol. 804, 181–201 (2014).
91. Ren, L. et al. Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma. Cancer Res. 72, 1001–1012 (2012).
92. Khanna, C. et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10, 182–186 (2004).
93. Lo Vasco, V. R., Leopizzi, M., Puggioni, C. & Della Rocca, C. Ezrin silencing remodulates the expression of Phosphoinositide-specific Phospholipase C enzymes in human osteosarcoma cell lines. J. Cell Commun. Signal. 8, 219–229 (2014).
94. Wu, M.-S. et al. CDC20 and its downstream genes: potential prognosis factors of osteosarcoma. Int. J. Clin. Oncol. 24, 1479–1489 (2019).
95. Wang, H., Liu, Z., Wu, P., Wang, H. & Ren, W. NUSAP1 Accelerates Osteosarcoma Cell Proliferation and Cell Cycle Progression via Upregulating CDC20 and Cyclin A2. Onco. Targets. Ther. 14, 3443–3454 (2021).
96. Liu Y., Ding J.-Y., Shen W.-L., Zhao X. & Fan S.-W. [Knockdown of cyclin A2 expression by small interfering RNA in MG-63 cells]. Zhonghua Zhong Liu Za Zhi 29, 670–675 (2007).
97. Shekhar, R. et al. The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression. J. Biol. Chem. 294, 4381–4400 (2019).
98. Mahmood, N., Mihalcioiu, C. & Rabbani, S. A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front. Oncol. 8, 24 (2018).
99. Haeckel, C. et al. Protease expression in dedifferentiated parosteal osteosarcoma. Arch. Pathol. Lab. Med. 123, 213–221 (1999).
100. Matsuyama, A., Wood, G. A., Speare, R., Schott, C. R. & Mutsaers, A. J. Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma. PLoS One 17, e0273811 (2022).
101. Dass, C. R. et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin. Exp. Metastasis 22, 643–652 (2005).
102. Borgatti, A. et al. Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. Mol. Cancer Ther. 16, 956–965 (2017).
103. de Bock, C. E. et al. Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. FEBS J. 272, 3572–3582 (2005).
104. Endo-Munoz, L. et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis. PLoS One 10, e0133592 (2015).
105. Jia, S.-F. et al. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther. 9, 260–266 (2002).
106. Worth, L. L., Jia, S. F., Zhou, Z., Chen, L. & Kleinerman, E. S. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res. 6, 3713–3718 (2000).
107. Tsuji, H. et al. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma. Cancer Gene Ther. 9, 747–755 (2002).
108. Charissoux, J. L., Grossin, L., Leboutet, M. J. & Rigaud, M. Treatment of experimental osteosarcoma tumors in rat by herpes simplex thymidine kinase gene transfer and ganciclovir. Anticancer Res. 19, 77–80 (1999).
109. Ramnaraine, M. et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res. 63, 6847–6854 (2003).
110. Ternovoi, V. V., Curiel, D. T., Smith, B. F. & Siegal, G. P. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab. Invest. 86, 748–766 (2006).
111. Li, H. et al. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53. Oncogene 40, 2785–2802 (2021).
112. Martínez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669–680 (2021).
113. Berger, M. F. & Mardis, E. R. The emerging clinical relevance of genomics in cancer medicine. Nat. Rev. Clin. Oncol. 15, 353–365 (2018).
114. Li, Q. & Kang, C. Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery. Int. J. Mol. Sci. 21, (2020).
115. Liu, G.-H., Chen, T., Zhang, X., Ma, X.-L. & Shi, H.-S. Small molecule inhibitors targeting the cancers. MedComm (2020) 3, e181 (2022).
116. Cohen, P., Cross, D. & Jänne, P. A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551–569 (2021).
117. Steeghs, N., Nortier, J. W. R. & Gelderblom, H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14, 942–953 (2007).
118. Li, S. Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. Front. Oncol. 11, 664853 (2021).
119. Wang, G. et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int. J. Cancer 145, 979–993 (2019).
120. Wang, G. et al. Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo. Front. Pharmacol. 12, 798837 (2021).
121. Long, Z.-Y. et al. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review. Ann. Palliat. Med. 10, 7073–7082 (2021).
122. Tian, S. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102, 1374–1380 (2011).
123. Aoyama, T. & Yoshikawa, T. Targeted therapy: Apatinib - new third-line option for refractory gastric or GEJ cancer. Nat. Rev. Clin. Oncol. 13, 268–270 (2016).
124. Liu, K. et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 8, e3015 (2017).
125. Xie, L. et al. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist 24, e542–e550 (2019).
126. Geller, J. I. et al. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124, 4548–4555 (2018).
127. Keating, G. M. Axitinib: a review in advanced renal cell carcinoma. Drugs 75, 1903–1913 (2015).
128. Choueiri, T. K. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr. Opin. Investig. Drugs 9, 658–671 (2008).
129. Ranieri, G. et al. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. Int. J. Mol. Sci. 18, (2017).
130. Fioramonti, M. et al. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Sci. Rep. 8, 4177 (2018).
131. Wang, J.-H., Zeng, Z., Sun, J., Chen, Y. & Gao, X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol. Res. 173, 105869 (2021).
132. Italiano, A. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446–455 (2020).
133. Wedge, S. R. et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389–4400 (2005).
134. Morton, C. L. et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 566–571 (2012).
135. Fox, E. et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 28, 5174–5181 (2010).
136. van Cruijsen, H. et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur. J. Cancer 46, 901–911 (2010).
137. Choi, K.-M. et al. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer. Int. J. Mol. Sci. 21, (2020).
138. Marley, K., Gullaba, J., Seguin, B., Gelberg, H. B. & Helfand, S. C. Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs. Transl. Oncol. 8, 231–238 (2015).
139. Ding, X. et al. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study. Anticancer Drugs 34, 877–882 (2023).
140. Zhao, Y. & Adjei, A. A. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 20, 660–673 (2015).
141. Iqbal, N. & Iqbal, N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 357027 (2014).
142. Gai, Q.-J. et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther 7, 33 (2022).
143. Benini, S. et al. Redundancy of autocrine loops in human osteosarcoma cells. Int. J. Cancer 80, 581–588 (1999).
144. Bond, M. et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr. Blood Cancer 50, 254–258 (2008).
145. Gobin, B. et al. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PLoS One 9, e90795 (2014).
146. Suyama, K. & Iwase, H. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control 25, 1073274818789361 (2018).
147. Gaspar, N. et al. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆. ESMO Open 6, 100250 (2021).
148. Gaspar, N. et al. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 22, 1312–1321 (2021).
149. Yoon, H.-Y., Park, S., Kim, D. S. & Song, J. W. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir. Res. 19, 203 (2018).
150. Zhang, W. et al. Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth. Cell Rep. 24, 1266–1277.e5 (2018).
151. Kallus, S. et al. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine 14, 2632–2643 (2018).
152. Sloan, B. & Scheinfeld, N. S. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Investig. Drugs 9, 1324–1335 (2008).
153. Kumar, S. et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17, 5656–5667 (2011).
154. Longhi, A. et al. Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncol. 58, 124–128 (2019).
155. Wilhelm, S. M. et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245–255 (2011).
156. Pan, P.-J., Liu, Y.-C. & Hsu, F.-T. Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. J. Clin. Med. Res. 8, (2019).
157. Duffaud, F. et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 20, 120–133 (2019).
158. Davis, L. E. et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J. Clin. Oncol. 37, 1424–1431 (2019).
159. Coventon, J. A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma. J Bone Oncol 8, 4–7 (2017).
160. Grignani, G. et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 16, 98–107 (2015).
161. Papaetis, G. S. & Syrigos, K. N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23, 377–389 (2009).
162. Motzer, R. J., Escudier, B., Gannon, A. & Figlin, R. A. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist 22, 41–52 (2017).
163. Kumar, R. M. R., Arlt, M. J., Kuzmanov, A., Born, W. & Fuchs, B. Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model. Am. J. Cancer Res. 5, 2156–2168 (2015).
164. Duan, X. L., Guo, J. P., Li, F., Xiu, C. & Wang, H. Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice. Future Oncol. 16, 1815–1824 (2020).
165. Penel-Page, M. et al. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer 15, 854 (2015).
166. McCarthy, E. F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 26, 154–158 (2006).
167. Esfahani, K. et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 27, S87–S97 (2020).
168. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317–327 (2010).
169. Nelson, P. N. et al. Monoclonal antibodies. Mol. Pathol. 53, 111–117 (2000).
170. Zahavi, D. & Weiner, L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel) 9, (2020).
171. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987–989 (2001).
172. Raouf, S., Bertelli, G., Ograbek, A., Field, P. & Tran, I. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncol. 15, 543–561 (2019).
173. Navid, F. et al. A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. Int. J. Cancer 141, 1469–1477 (2017).
174. Pfister, N. T. et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 29, 1298–1315 (2015).
175. Lowery, C. D. et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget 10, 5523–5533 (2019).
176. Hashimoto, K., Nishimura, S. & Akagi, M. Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma. Diagnostics (Basel) 10, (2020).
177. Wen, Y. et al. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. Cancer Lett. 547, 215887 (2022).
178. Shimizu, T. et al. The effect of immune checkpoint inhibitors on lung metastases of osteosarcoma. J. Pediatr. Surg. 52, 2047–2050 (2017).
179. Dhupkar, P., Gordon, N., Stewart, J. & Kleinerman, E. S. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 7, 2654–2664 (2018).
180. Zhang, M.-L., Chen, L., Li, Y.-J. & Kong, D.-L. PD L1/PD 1 axis serves an important role in natural killer cell induced cytotoxicity in osteosarcoma. Oncol. Rep. 42, 2049–2056 (2019).
181. Lussier, D. M. et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J. Immunother. 38, 96–106 (2015).
182. Liu, X. et al. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ. Health Prev. Med. 24, 79 (2019).
183. Yoshida, K. et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer 20, 25 (2020).
184. Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–1501 (2017).
185. Le Cesne, A. et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur. J. Cancer 119, 151–157 (2019).
186. Geoerger, B. et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol. 21, 134–144 (2020).
187. Davis, K. L. et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 21, 541–550 (2020).
188. Boye, K. et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol. Immunother. 70, 2617–2624 (2021).
189. Contardi, E. et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer 117, 538–550 (2005).
190. Kawano, M., Itonaga, I., Iwasaki, T. & Tsumura, H. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol. Rep. 29, 1001–1006 (2013).
191. Eroglu, Z. et al. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur. J. Cancer 51, 2689–2697 (2015).
192. Merchant, M. S. et al. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin. Cancer Res. 22, 1364–1370 (2016).
193. Cui, J. et al. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. J. Orthop. Res. 38, 2362–2372 (2020).
194. Slemmons, K. K., Mukherjee, S., Meltzer, P., Purcell, J. W. & Helman, L. J. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr. Blood Cancer 68, e28771 (2021).
195. Hingorani, P. et al. ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Mol. Cancer Ther. 20, 535–540 (2021).
196. Demetri, G. D. et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin. Cancer Res. 27, 3556–3566 (2021).
197. Tabak, S. A., Khalifa, S. E. & Fathy, Y. HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients. Open Access Maced J Med Sci 6, 1555–1560 (2018).
198. Park, J. A. & Cheung, N.-K. V. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J. Hematol. Oncol. 13, 172 (2020).
199. Ebb, D. et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J. Clin. Oncol. 30, 2545–2551 (2012).
200. Wen, Y. H. et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum. Pathol. 38, 1184–1191 (2007).
201. Sevelda, F. et al. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J. Exp. Clin. Cancer Res. 34, 134 (2015).
202. Wang, S. et al. Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. Acta Biochim. Biophys. Sin. 53, 317–324 (2021).
203. Pahl, J. H. W. et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin. Cancer Res. 18, 432–441 (2012).
204. Li, Y.-S., Liu, Q., He, H.-B. & Luo, W. The possible role of insulin-like growth factor-1 in osteosarcoma. Curr. Probl. Cancer 43, 228–235 (2019).
205. Houghton, P. J. et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 921–926 (2010).
206. Kolb, E. A. et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr. Blood Cancer 55, 67–75 (2010).
207. Malempati, S. et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 30, 256–262 (2012).
208. Kolb, E. A. et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr. Blood Cancer 61, 1816–1821 (2014).
209. Kopp, L. M. et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children’s Oncology Group. Eur. J. Cancer 121, 177–183 (2019).
210. Smeester, B. A. et al. SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. Oncogene 39, 1049–1062 (2020).
211. Lussier, D. M., Johnson, J. L., Hingorani, P. & Blattman, J. N. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3, 21 (2015).
212. Xie, M. et al. Identification of genes contributing to cisplatin resistance in osteosarcoma cells. FEBS Open Bio 13, 164–173 (2023).
213. Clavijo, P. E. et al. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. Cancer Immunol Res 7, 282–291 (2019).
214. Liu, J. et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J. Hematol. Oncol. 15, 28 (2022).
215. Thamm, D. H. et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin. Cancer Res. 11, 4827–4834 (2005).
216. Hashii, Y. et al. WT1 peptide immunotherapy for cancer in children and young adults. Pediatr. Blood Cancer 55, 352–355 (2010).
217. Himoudi, N. et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin. Transl. Oncol. 14, 271–279 (2012).
218. Finocchiaro, L. M. E., Villaverde, M. S., Gil-Cardeza, M. L., Riveros, M. D. & Glikin, G. C. Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas. Res. Vet. Sci. 91, 230–234 (2011).
219. Gentschev, I. et al. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 4, 84–89 (2013).
220. Cascini, C. et al. Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma. J. Exp. Clin. Cancer Res. 42, 154 (2023).
221. Mason, N. J. et al. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clin. Cancer Res. 22, 4380–4390 (2016).
222. Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).
223. Heymann, M.-F., Lézot, F. & Heymann, D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell. Immunol. 343, 103711 (2019).
224. Lu, Y. et al. Novel Immunotherapies for Osteosarcoma. Front. Oncol. 12, 830546 (2022).
225. Fritzsching, B. et al. CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology 4, e990800 (2015).
226. Sarnaik, A. A., Hwu, P., Mulé, J. J. & Pilon-Thomas, S. Tumor-infiltrating lymphocytes: A new hope. Cancer Cell 42, 1315–1318 (2024).
227. Park, J. A. & Cheung, N.-K. V. Promise and challenges of T cell immunotherapy for osteosarcoma. Int. J. Mol. Sci. 24, (2023).
228. Casanova, J. M. et al. Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival. Cancers 13, (2021).
229. Zhou, X., Wu, J., Duan, C. & Liu, Y. Retrospective analysis of adoptive TIL therapy plus anti-PD1 therapy in patients with chemotherapy-resistant metastatic osteosarcoma. J. Immunol. Res. 2020, 7890985 (2020).
230. Wang, C., Li, M., Wei, R. & Wu, J. Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. J Bone Oncol 25, 100332 (2020).
231. Yu, S. & Yao, X. Advances on immunotherapy for osteosarcoma. Mol. Cancer 23, 192 (2024).
232. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
233. Rohaan, M. W., Wilgenhof, S. & Haanen, J. B. A. G. Adoptive cellular therapies: the current landscape. Virchows Arch. 474, 449–461 (2019).
234. Watanabe, K. et al. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells. Cancer Sci. 110, 40–51 (2019).
235. Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer 9, (2021).
236. Rafei, H., Daher, M. & Rezvani, K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br. J. Haematol. 193, 216–230 (2021).
237. Terlikowska, K. M., Dobrzycka, B. & Terlikowski, S. J. Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. Int. J. Mol. Sci. 22, (2021).
238. Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689–702 (2009).
239. Ahmed, N. et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779–1787 (2009).
240. Rainusso, N. et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19, 212–217 (2012).
241. Talbot, L. J. et al. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells. Front. Immunol. 12, 691741 (2021).
242. Zhang, Q. et al. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer 22, 1124 (2022).
243. Hidalgo, L. et al. Switchable CAR T cell strategy against osteosarcoma. Cancer Immunol. Immunother. 72, 2623–2633 (2023).
244. Chulanetra, M. et al. GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. Am. J. Cancer Res. 10, 674–687 (2020).
245. Fernández, L. et al. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. Clin. Cancer Res. 23, 5824–5835 (2017).
246. Huang, G. et al. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72, 271–281 (2012).
247. Wang, Y. et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J. Exp. Clin. Cancer Res. 38, 168 (2019).
248. Mensali, N. et al. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nat. Commun. 14, 3375 (2023).
249. Zhang, X., Zhang, H., Lan, H., Wu, J. & Xiao, Y. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Front. Immunol. 14, 1101495 (2023).
S
250. Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).
251. Wang, L., Li, W. & Pan, Y. The Eph/Ephrin system in primary bone tumor and bone cancer pain. Aging 15, 7324–7332 (2023).